Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

lease includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety and progression free survival information for pixantrone which is still being assembled, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, determination the FDA that the PIX301 trial is insufficient to support an NDA filing, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T : 206.272.4347

F : 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 ... their own employees to capture critical product and ... there are many benefits to employee-based studies, it ... to leverage their own internal employees to capture ... recent study by benchmarking firm, Best Practices, LLC, ...
(Date:7/2/2015)... 2, 2015  Fort Lauderdale-based investment banking firm, ... that its Consumer Group completed the sale of ... plc (ISE: KRZ) ("Kerry"), one of the leading ... as well as functional ingredients and actives for ... Turner served as the exclusive financial advisor to ...
(Date:7/2/2015)... According to a new market research report " ... Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, ... MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 Billion ... 2020, at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
Breaking Medicine Technology:Leveraging Employee Insights to Produce Cutting-Edge Market Research 2Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4
... 11, 2011 The U.S. Food and Drug Administration ... help manage potential organ rejection in kidney transplant patients. ... level of everolimus, a drug that helps prevent rejection ... ) Everolimus, marketed under the trade ...
... U.S. Food and Drug Administration today approved the Selenia ... three-dimensional (3-D) images of the breast for breast cancer ... A mammogram is a safe, low-dose ... for early detection of breast cancer. However, with the ...
Cached Medicine Technology:FDA Clears Test to Help Patients With Kidney Transplants 2FDA Approves First 3-D Mammography Imaging System 2
(Date:7/3/2015)... Red Deer, Alberta (PRWEB) , ... July 03, 2015 , ... ... Camp host their 24-Hour Train-a-Thon where they provide members of the Red Deer community ... This year’s full day of fitness training, games, food, events and entertainment raised thousands ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on ... Samir Becic emphatically declared a war on obesity in the United States. , "Obesity ... must understand the magnitude of this discovery. For that reason, I am declaring, along ...
(Date:7/2/2015)... ... , ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, ... his first poem, and three years later he was publishing an entire book of poetry. ... the world. "I have always believed that the best way to lift yourself up, is ...
(Date:7/2/2015)... ... ... Six months ahead of his 80th birthday, Don Stevenson has reached the ... the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State three ... He left Glasgow, Mont. yesterday morning and is making his way to Wolf Point. ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... of Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine surgery team ... disc herniations, sprains, strains, bursitis, and tendonitis. Along with the spine and spine ...
Breaking Medicine News(10 mins):Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3
... that fetal cell transplantation for patients with Parkinson’s ... their medications altogether.// ,Parkinson’s disease is ... with Parkinson’s lack the chemical dopamine, which is ... aborted human fetal tissue to replace the lost ...
... groggy and restless every morning. What many don't know is that ... be what's keeping them awake. Sleep specialists say as we age, ... but they also say its never too late to get back ... to do is to cut out caffeine after noon and to ...
... of a recent study researchers say annual flu vaccines in ... hospitalizations, respiratory tract infections, and other key measures. ,The ... form of the flu virus in their shots. Children who ... be somewhat more protected. However, for children under age 2 ...
... 140th Midwinter Meeting that begins in US today, it ... take a peek to some very innovative and original ... The convention is also one of the largest exhibitions ... showcase of products from 46 countries will include flavored ...
... examining 1,116 sets of twins and their mothers to see ... children's first five years // of life and children's antisocial ... mothers were found to have increased problems with conduct and ... showed maternal depression after the twins' birth and the likeliness ...
... Southern California School of Dentistry has devised a test to ... saliva// to measure the relative concentration of various sugar chains ... same as those present in the teeth surface. Some sugar ... certain bacteria to bond with the tooth. Each individual sugar ...
Cached Medicine News:
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: